A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor

British Journal of Cancer

Volumn 74, Issue 3, 1996, Pages 479-481

  Smith, I ^a,k   Jones, A ^a   Spielmann, M ^b   Namer, M ^c   Green, M D ^d   Bonneterre, J ^e   Wander, H E ^f   Hatschek, T ^g   Wilking, N ^h   Zalcberg, J ⁱ   Spiers, J ^j   Seymour, L ^j  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CENTRE ANTOINE LACASSAGNE   (France)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e CENTRE OSCAR LAMBRET   (France)

^f Arzt für Innere Medizin   (Sweden)

^g LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^h Radiumhemmet Karolinska   (Sweden)

ⁱ Austin Medical Centre   (Australia)

^j ASTRAZENECA   (United Kingdom)

^k ROYAL MARSDEN HOSPITAL   (United Kingdom)

more..

Author keywords

'Tomudex'; Breast cancer; Thymidylate synthase inhibitor; ZD1694

Indexed keywords

AMINOTRANSFERASE; CYTOTOXIC AGENT; HORMONE; RALTITREXED; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG FATALITY; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOPENIA; LIVER METASTASIS; MUCOSA INFLAMMATION; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 9344267746     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.386     Document Type: Article

References (11)

1. ADENIS A, CUNNINGHAM D, VAN CUTSEM E, ZALCBERG J, FRANCOIS E, SCHORNAGEL JH, GREEN M, STARKHAMMER H, PEREZ-MANGA G AND SEYMOUR L (STUDY GROUP). (1994). ZD1694 (ZD1694), a new active agent in the treatment of advanced colorectal cancer. Ann. Oncol., 5, (suppl. 8), 189.
2. CHEVALIER B, FUMOLEAU P, KERBRAT P, DIERAS V, ROCHE H, KRAKOWSKI I, AZLI N, BAYSSAS M, LENTZ MA AND VAN GLABBEKE M. (1995). Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the clinical screening cooperative group of the European Organisation for the Research and Treatment of Cancer. J. Clin. Oncol., 13, 314-322.
3. CLARKE SJ, WARD J, DE BOER M, PLANTING A, VERWEIJ J, SUTCLIFFE F, AZAB M AND JUDSON IR. (1994). Phase I study of the new thymidylate synthase inhibitor ZD1694 (ZD1694) in patients with advanced malignancy. Ann. Oncol., 5, (suppl. 5), 132.
4. CUNNINGHAM D, ZALCBERG J, SMITH IE, GORE M, PAZDUR R, BURRIS H, AZAB M AND KENNEALEY G (STUDY GROUP). (1994). ZD1694: a novel thymidylate synthase (TS) inhibitor with clinical antitumour activity in a range of solid tumours. Ann. Oncol., 5, (suppl. 8), 179.
5. FLEMING TR. (1982). One sample multiple testing for phase II clinical trials. Biometrics, 38, 143-151.
6. GIANNI L, CAPRI G, MUNZONE E AND STRANEO M (1994). Paclitaxel (taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines. Semin. Oncol., 21, 29-33.
7. HAYWARD JL, CARBONE PP, HEUSON JC, KUMAOKA S, SEGALOFF A AND RUBENS RD. (1977). Assessment of response to therapy in advanced breast cancer. Eur J Cancer, 13, 89-94.
8. HOOGSTRATEN B AND FABIAN C. (1979). A reappraisal of single drugs in advanced breast cancer. Cancer Clin. Trials, 2, 101-109.
9. JACKMAN AL, GIBSON W, BROWN M, KIMBELL R AND BOYLE FT. (1993). The role of the reduced folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. Adv. Exp. Med. Biol., 339, 265-276.
10. THE DECLARATION OF HELSINKI. (1989). Recommendations guiding physicians in biomedical research involving human subjects. 41st World Medical Assembly, Hong Kong.
11. WORLD HEALTH ORGANIZATION. (1979). WHO Handbook for Reporting Results of Cancer Treatment, World Health Organization: Geneva.